Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients

BACKGROUND. Type 1 diabetes (T1D) results from destruction of pancreatic β cells by autoreactive effector T cells. We hypothesized that the immunomodulatory drug alefacept would result in targeted quantitative and qualitative changes in effector T cells and prolonged preservation of endogenous insul...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Invest
Autors principals: Rigby, Mark R., Harris, Kristina M., Pinckney, Ashley, DiMeglio, Linda A., Rendell, Marc S., Felner, Eric I., Dostou, Jean M., Gitelman, Stephen E., Griffin, Kurt J., Tsalikian, Eva, Gottlieb, Peter A., Greenbaum, Carla J., Sherry, Nicole A., Moore, Wayne V., Monzavi, Roshanak, Willi, Steven M., Raskin, Philip, Keyes-Elstein, Lynette, Long, S. Alice, Kanaparthi, Sai, Lim, Noha, Phippard, Deborah, Soppe, Carol L., Fitzgibbon, Margret L., McNamara, James, Nepom, Gerald T., Ehlers, Mario R.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2015
Matèries:
Clinical Medicine
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4623571/
https://ncbi.nlm.nih.gov/pubmed/26193635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI81722
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars